Author Correction: CIS is a potent checkpoint in NK cell–mediated tumor immunity (Nature Immunology, (2016), 17, 7, (816-824), 10.1038/ni.3470);CIS is a potent checkpoint in NK cell-mediated tumor immunity

Nature Immunology

Volumn 17, Issue 7, 2016, Pages 816-824

  Delconte, Rebecca B ^a,b   Kolesnik, Tatiana B ^a   Dagley, Laura F ^a,b   Rautela, Jai ^a,b   Shi, Wei ^a,b   Putz, Eva M ^c   Stannard, Kimberley ^c   Zhang, Jian Guo ^a,b   Teh, Charis ^a,b   Firth, Matt ^a,b   Ushiki, Takashi ^a,b   Andoniou, Christopher E ^d   Degli Esposti, Mariapia A ^d   Sharp, Phillip P ^a,b   Sanvitale, Caroline E ^e   Infusini, Giuseppe ^a   Liau, Nicholas P D ^a,b   Linossi, Edmond M ^a,b   Burns, Christopher J ^a,b   Carotta, Sebastian ^a,b   Gray, Daniel H D ^a,b   Seillet, Cyril ^a,b   Hutchinson, Dana S ^f   Belz, Gabrielle T ^a,b   Webb, Andrew I ^a,b   Alexander, Warren S ^a,b   Li, Shawn S ^g   Bullock, Alex N ^e   Babon, Jeffery J ^a,b   Smyth, Mark J ^c,h   Nicholson, Sandra E ^a,b   Huntington, Nicholas D ^a,b   more..

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f MONASH UNIVERSITY   (Australia)

^g WESTERN UNIVERSITY   (Canada)

^h UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE INDUCIBLE SH2 CONTAINING PROTEIN; GAMMA INTERFERON; INTERLEUKIN 15; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; PROTEASOME; REGULATOR PROTEIN; STAT PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CYTOKINE INDUCIBLE SH2-CONTAINING PROTEIN; JAK1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL LUNG METASTASIS; FEMALE; GENE DELETION; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MELANOMA; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CYTOTOXICITY; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; NEOPLASMS; PROCEDURES;

ANIMALS; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-15; JANUS KINASE 1; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84969760211     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/s41590-023-01714-8     Document Type: Erratum

References (61)

1. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
2. Shin, D. S. & Ribas, A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr. Opin. Immunol. 33, 23-35 (2015).
3. Restifo, N. P., Smyth, M. J. & Snyder, A. Acquired resistance to immunotherapy and future challenges. Nat. Rev. Cancer 16, 121-126 (2016).
4. Vivier, E., Ugolini, S., Blaise, D., Chabannon, C. & Brossay, L. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239-252 (2012).
5. Huntington, N. D., Vosshenrich, C. A. & Di Santo, J. P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7, 703-714 (2007).
6. Huntington, N. D. The unconventional expression of IL-15 and its role in NK cell homeostasis. Immunol. Cell Biol. 92, 210-213 (2014).
7. Verdeil, G., Puthier, D., Nguyen, C., Schmitt-Verhulst, A. M. & Auphan-Anezin, N. STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors. J. Immunol. 176, 4834-4842 (2006).
8. Huntington, N. D. et al. Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat. Immunol. 8, 856-863 (2007).
9. Sathe, P. et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat. Commun. 5, 4539 (2014).
10. Floros, T. & Tarhini, A. A. Anticancer Cytokines: Biology and Clinical Effects of Interferon-2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin. Oncol. 42, 539-548 (2015).
11. Hilton, D. J. et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. USA 95, 114-119 (1998).
12. Linossi, E. M., Babon, J. J., Hilton, D. J. & Nicholson, S. E. Suppression of cytokine signaling: the SOCS perspective. Cytokine Growth Factor Rev. 24, 241-248 (2013).
13. Zhang, J. G. et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA 96, 2071-2076 (1999).
14. Yasukawa, H. et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18, 1309-1320 (1999).
15. Kershaw, N. J. et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat. Struct. Mol. Biol. 20, 469-476 (2013).
16. Yoshimura, A. et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14, 2816-2826 (1995).
17. Matsumoto, A. et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89, 3148-3154 (1997).
18. Aman, M. J. et al. CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling. J. Biol. Chem. 274, 30266-30272 (1999).
19. Yang, X. O. et al. The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation. Nat. Immunol. 14, 732-740 (2013).
20. Palmer, D. C. et al. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J. Exp. Med. 212, 2095-2113 (2015).
21. Burns, C. J., Segal, D. & Wilks, A. F. in JAK-STAT Signalling Methods and Protocols (eds S. E. Nicholson & N. A. Nicola) Chapter 7, 99-112 (Human Press, USA, 2013).
22. Mlecnik, B. et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl. Med. 6, 228ra37 (2014).
23. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
24. Larkin, J. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373, 23-34 (2015).
25. Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017 (2015).
26. Homet Moreno, B. & Ribas, A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br. J. Cancer 112, 1421-1427 (2015).
27. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
28. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
29. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
30. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
31. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
32. Knorr, D. A., Bachanova, V., Verneris, M. R. & Miller, J. S. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin. Immunol. 26, 161-172 (2014).
33. Chan, C. J. et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 15, 431-438 (2014).
34. Blake, S. J. et al. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 6, 446-459 (2016).
35. Croker, B. A. et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4, 540-545 (2003).
36. Alexander, W. S. et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98, 597-608 (1999).
37. Narni-Mancinelli, E. et al. Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc. Natl. Acad. Sci. USA 108, 18324-18329 (2011).
38. Boyman, O. et al. Selectively expanding subsets of T cells in mice by injection of interleukin-2/antibody complexes: implications for transplantation tolerance. Transplant. Proc. 44, 1032-1034 (2012).
39. Kolesnik, T. B. & Nicholson, S. E. Analysis of Suppressor of Cytokine Signalling (SOCS) gene expression by real-time quantitative PCR. Methods Mol. Biol. 967, 235-248 (2013).
40. Nicholson, S. E., Novak, U., Ziegler, S. F. & Layton, J. E. Distinct regions of the granulocyte colony-stimulating factor receptor are required for tyrosine phosphorylation of the signaling molecules JAK2, Stat3, and p42, p44MAPK. Blood 86, 3698-3704 (1995).
41. Linossi, E. M. et al. Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. PLoS One 8, e70536 (2013).
42. Burns, C. J. et al. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg. Med. Chem. Lett. 19, 5887 (2009).
43. Cytopia Research. Phenyl amino pyrimidine compounds and uses thereof. US Patent WO2008/109943 A1 (2008).
44. Schirle, M. et al. in Kinase Inhibitors Vol. 795 Methods in Molecular Biology (ed Bernhard Kuster) Chapter 11, 161-177 (Humana Press, 2012).
45. Wisniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. Nat. Methods 6, 359-362 (2009).
46. Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794-1805 (2011).
47. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p. p. b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372 (2008).
48. Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics 13, 2513-2526 (2014).
49. Keilhauer, E. C., Hein, M. Y. & Mann, M. Accurate protein complex retrieval by affinity enrichment mass spectrometry (AE-MS) rather than affinity purification mass spectrometry (AP-MS). Mol. Cell. Proteomics 14, 120-135 (2015).
50. Bullock, A. N., Debreczeni, J. E., Edwards, A. M., Sundström, M. & Knapp, S. Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc. Natl. Acad. Sci. USA 103, 7637-7642 (2006).
51. Li, S. S. & Wu, C. Using peptide array to identify binding motifs and interaction networks for modular domains. Methods Mol. Biol. 570, 67-76 (2009).
52. Babon, J. J. & Murphy, J. M. In vitro JAK kinase activity and inhibition assays. Methods Mol. Biol. 967, 39-55 (2013).
53. Babon, J. J. et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36, 239-250 (2012).
54. Ferrari de Andrade, L. et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res. 74, 7298-7308 (2014).
55. Gilfillan, S. et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J. Exp. Med. 205, 2965-2973 (2008).
56. Stagg, J. et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 71, 2892-2900 (2011).
57. Stagg, J. et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. USA 108, 7142-7147 (2011).
58. Swann, J. B. et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178, 7540-7549 (2007).
59. Rautela, J. et al. Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer. Cancer Immunol. Res. 3, 1207-1217 (2015).
60. Johnstone, C. N. et al. Functional and molecular characterisation of EO771. LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis. Model. Mech. 8, 237-251 (2015).
61. Allard, B., Pommey, S., Smyth, M. J. & Stagg, J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res. 19, 5626-5635 (2013).